These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 38477313

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gepants - a long way to cure: a narrative review.
    Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F.
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [Abstract] [Full Text] [Related]

  • 5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 6. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Sep; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD.
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R, Shebley M, Trugman JM.
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Atogepant for migraine.
    Bedrin K, Ailani J.
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society.
    Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
    [Abstract] [Full Text] [Related]

  • 19. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC.
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.